New Patient Access Program to Expand Reimbursement Coverage for prodisc® L Lumbar Total Disc Replacement is Launched by Centinel Spine

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

October 27, 2020

Patient Access Program will be particularly focused on providing reimbursement support for two-level lumbar disc replacement procedures using prodisc® L, the only lumbar Total Disc Replacement product in the world that is FDA-approved for two-level use. The news was announced today by Centinel Spine.

In April, Centinel Spine announced FDA approval of two-level indications for the prodisc® L Lumbar Total Disc Replacement (TDR) system. This expanded indication allows for the treatment of a significant number of patients who suffer with two-level Degenerative Disc Disease and were not previously able to gain access to the technology. Long term data from FDA studies demonstrate that lumbar total disc replacement maintains spinal motion, decreases the occurrence of adjacent segment disease, and allows for faster recovery and return to activities of daily living.

The Patient Access Program has been developed and will be administered in conjunction with Musculoskeletal Clinical Regulatory Advisors (MCRA), a leading healthcare industry advisory firm founded in 2004 and serving more than 500 clients worldwide. MCRA is known for successfully navigating complex global reimbursement pathways for new technologies. The program will support reimbursement coding questions and the case management process on behalf of providers and patients, advocating for patient access throughout the benefit verification, prior authorization and appeals processes.

“The Patient Access Program is here to provide patients the benefit of covered access to a motion-preserving technology clinically proven over the last 30 years,” stated Centinel Spine CEO Steve Murray. “We have been encouraged by the continued progress in expanded coverage for single-level lumbar TDR procedures, and continue work to advance these same coverage benefits for patients with two-level disc disease,” Murray concluded.

Centinel Spine stands alone as the only company with FDA-approved cervical and lumbar total disc replacement devices. The prodisc family of devices now consists of six devices, including an anterior and anterior-lateral approach lumbar disc replacement and four cervical disc replacement implants with a variety of endplate configurations designed to enable surgeons to better suit patient anatomy. New developments to the family of products include a recently initiated two-level clinical trial comparing the prodisc C Vivo and prodisc C SK devices with an approved TDR product as a control, in order to validate their safety and effectiveness in an FDA IDE study.

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.